Parmar, Jasneet http://orcid.org/0000-0002-0285-8698
von Jonquieres, Georg http://orcid.org/0000-0002-7423-3355
Gorlamandala, Nagarajesh http://orcid.org/0000-0003-4385-5271
Chung, Brandon
Craig, Amanda J. http://orcid.org/0000-0002-7197-4369
Pinyon, Jeremy L.
Birnbaumer, Lutz http://orcid.org/0000-0002-0775-8661
Klugmann, Matthias http://orcid.org/0000-0003-0574-612X
Moorhouse, Andrew J. http://orcid.org/0000-0001-7957-2498
Power, John M. http://orcid.org/0000-0002-2478-8416
Housley, Gary D. http://orcid.org/0000-0002-8413-588X
Funding for this research was provided by:
University of New South Wales
Article History
Received: 3 May 2023
Revised: 29 June 2023
Accepted: 30 June 2023
First Online: 18 July 2023
Declarations
:
: Dr. Gary Housley is the chair of the Scientific Advisory Board at Nyrada Inc and holds stock in the company. Dr. Jasneet Parmar is a fulltime employee of Nyrada Inc. Nyrada Inc is currently developing a small molecule inhibitor of TRPC ion channels. The experiments described here were conducted prior to their respective roles with Nyrada and were not funded by the Company. The TRPC channel target for brain injury neuroprotection has been declared in public statements by Nyrada Inc, which acknowledges GDH and UNSW. A patent filed on the block of TRPC3 channels for neuroprotection (AU2013286815B2; ceased) includes AJC, GDH, MK, AJM, JMP as inventors and UNSW as the assignee (NewSouth Innovations Pty Ltd).